Objectives To investigate the effects of personal calcium supplement use on cardiovascular risk in the Women's Health Initiative Calcium/Vitamin D Supplementation Study (WHI CaD Study), using the WHI dataset, and to update the recent meta-analysis of calcium supplements and cardiovascular risk. Design Reanalysis of WHI CaD Study limited access dataset and incorporation in meta-analysis with eight other studies. Data source WHI CaD Study, a seven year, randomised, placebo controlled trial of calcium and vitamin D (1g calcium and 400 IU vitamin D daily) in 36 282 community dwelling postmenopausal women. Main outcome measures Incidence of four cardiovascular events and their combinations (myocardial infarction, coronary revascularisation, death from coronary heart disease, and stroke) assessed with patient-level data and trial-level data. Results In the WHI CaD Study there was an interaction between personal use of calcium supplements and allocated calcium and vitamin D for cardiovascular events. In the 16 718 women (46%) who were not taking personal calcium supplements at randomisation the hazard ratios for cardiovascular events with calcium and vitamin D ranged from 1.13 to 1.22 (P=0.05 for clinical myocardial infarction or stroke, P=0.04 for clinical myocardial infarction or revascularisation), whereas in the women taking personal calcium supplements cardiovascular risk did not alter with allocation to calcium and vitamin D. In meta-analyses of three placebo controlled trials, calcium and vitamin D increased the risk of myocardial infarction (relative risk 1.21 (95% confidence interval 1.01 to 1.44), P=0.04), stroke (1.20 (1.00 to 1.43), P=0.05), and the composite of myocardial infarction or stroke (1.16 (1.02 to 1.32), P=0.02). In metaanalyses of placebo controlled trials of calcium or calcium and vitamin D, complete trial-level data were available for 28 072 participants from eight trials of calcium supplements and the WHI CaD participants not taking personal calcium supplements. In total 1384 individuals had an incident myocardial infarction or stroke. Calcium or calcium and vitamin D increased the risk of myocardial infarction (relative risk 1.24 (1.07 to 1.45), P=0.004) and the composite of myocardial infarction or stroke (1.15 (1.03 to 1.27), P=0.009).
INTRODUCTION
Calcium supplements, with or without vitamin D, are widely used for the prevention and treatment of osteoporosis. Recently, we reported increases in rates of cardiovascular events in women allocated to calcium supplements in the Auckland Calcium Study, a five year randomised, placebo controlled trial in healthy older women, in which cardiovascular events were pre-specified secondary end points. 1 Subsequently, we carried out a meta-analysis of cardiovascular events in randomised, placebo controlled trials of calcium supplements (without vitamin D co-administration). 2 Calcium supplements significantly increased the risk of myocardial infarction by 31% in five trials involving 8151 participants where patient level data were available, and by 27% in 11 trials involving 11 921 participants where trial level data were available. 2 There were no statistically significant increases in the risk of stroke; the composite end point of myocardial infarction, stroke, or sudden death; or death (relative risks or hazard ratios ranged from 1.07 to 1.20) , but the metaanalyses did not have sufficient power to detect effect sizes of these magnitudes. 2 An important question that arises is whether coadministered calcium and vitamin D affects cardiovascular risk. The Women's Health Initiative reported no adverse effect of calcium and vitamin D (1 g calcium/400 IU vitamin D daily) on any cardiovascular end point in their large (n=36 282), seven year, randomised, placebo controlled trial. 3 4 However, 54% of the participants were taking personal (non-protocol) calcium supplements at randomisation and 47% were taking personal vitamin D supplements, effectively rendering this trial a comparison of higher dose and lower dose calcium and vitamin D for most of the participants.
Allowing clinical trial participants free access to the intervention being studied is unusual and has the potential to obscure both adverse and beneficial effects. We hypothesised that the frequent personal use of calcium supplements might have obscured an adverse effect of calcium and vitamin D on cardiovascular risk. Therefore, we analysed the limited access dataset of the Women's Health Initiative Calcium/ Vitamin D Supplementation Study (WHI CaD Study) to determine whether there were interactions between personal use of calcium supplements and allocation to calcium and vitamin D supplementation for cardiovascular events. Using data from women not using personal calcium supplements at randomisation in the study, we have updated our previous meta-analysis to provide the best current estimate of the effects of calcium supplements, with or without vitamin D, on the risk of cardiovascular events.
METHODS

Analyses of WHI CaD Study
The design and results of the WHI CaD Study have been published in full. 3 4 Medical records related to self reported medical events for myocardial infarction, stroke, and coronary revascularisation were adjudicated centrally by physician adjudicators using standardised definitions, and all deaths were also centrally adjudicated. 4 We obtained the WHI limited access, clinical trials dataset from the National Heart Lung and Blood Institute. A statistical analysis proposal was submitted to the institute before the database was made available.
We attempted to replicate the approach of the WHI investigators where possible, carrying out prespecified analyses looking for interactions between pre-specified subgroups based on use (no use v any use) and dose (0, 1-499, 500-999, ≥1000 mg/day) of personal calcium supplements at randomisation for cardiovascular events. We pre-specified assessment of four cardiovascular end points and their combinations: myocardial infarction, coronary revascularisation (coronary artery bypass grafting or percutaneous coronary intervention), death from coronary heart disease, and stroke. Serial electrocardiograms were carried out in the WHI CaD Study, allowing detection of silent myocardial infarctions. Because silent myocardial infarctions were not determined in any of the trials in our meta-analysis, we analysed data separately for clinical myocardial infarctions and total myocardial infarctions (including clinical and silent myocardial infarction). We have reported four different composite end points: total deaths from myocardial infarction or coronary heart disease (the major outcome reported in the WHI CaD Study); clinical myocardial infarction or coronary revascularisation (representing clinical coronary heart disease events); clinical myocardial infarction or stroke (the composite end point most similar to that used in our meta-analysis of calcium monotherapy trials); and total myocardial infarction, coronary revascularisation, and death from coronary heart disease (representing all coronary heart disease events).
We have reported the baseline characteristics at the time of randomisation to the WHI CaD Study, whereas the WHI investigators reported these characteristics at the time of entry to the WHI programme. For body mass index and for dietary and supplemental calcium intake, we used the latest value recorded between screening and one month after randomisation to the study.
To assess the effect of calcium and vitamin D on the time to first event for each end point, we used Cox proportional hazards models stratified by age, prevalent cardiovascular disease at baseline, and randomisation status in the WHI Postmenopausal Hormone Therapy Trials and Dietary Modification Trial, following the approach of the WHI investigators. 3 4 Comparisons between subgroups were assessed using interaction terms. The assumption of proportional hazards was tested by performing a test for proportionality of the interaction between variables included in the model and the logarithm of time.
Meta-analysis of calcium with or without vitamin D Two recent systematic reviews have independently reviewed the effects of calcium and vitamin D supplements on vascular events. 5 6 These reviews identified two trials of co-administered calcium and vitamin D with cardiovascular outcome data: the WHI CaD Study and a small, one year trial of 191 participants that reported 11 cardiovascular events during followup but did not provide specific details about these events. 7 During the process of gathering data for our meta-analysis of calcium monotherapy, we obtained previously unpublished data from two studies that compared co-administered calcium and vitamin D with placebo. 8 9 We therefore pooled data from these two studies together with the results for the WHI CaD Study participants who were not taking personal calcium supplements at randomisation in a meta-analysis of the effect of calcium and vitamin D on cardiovascular risk.
We then updated our previous meta-analysis of calcium supplements by including the results for the WHI CaD Study participants not taking personal calcium supplements at randomisation, to determine the effect of calcium with or without vitamin D on cardiovascular risk. Of note, only 1.2% of participants were taking non-protocol calcium supplements in the trials contributing patient-level data in our previous metaanalysis of calcium supplements, 2 and two of the six studies contributing trial-level data permitted nonprotocol calcium supplements. 9 10 We used the same methods as for our previous meta-analysis: 2 the effect of calcium or calcium and vitamin D on the time to first event was assessed with Cox proportional hazards models stratified by study for patient-level data, and trial-level summary data were pooled using random effects models. 2 The assumption of proportional hazards was tested as described above.
All analyses were performed using SAS version 9.1 (SAS Institute, Cary NC, USA) or Comprehensive Meta-analysis version 2 (Biostat, Englewood NJ, USA). All tests were two tailed and P<0.05 was considered significant. Table 1 shows the characteristics of the participants at randomisation to the WHI CaD Study grouped by personal use of calcium supplements: 54% of participants were taking personal calcium supplements. The baseline characteristics of the participants allocated to calcium and vitamin D or to placebo seemed well matched for the subgroups defined by use of personal calcium supplement. However, participants using personal calcium supplements differed from those not using personal supplements in some factors associated with cardiovascular disease: age, body mass index, blood pressure, use of hormone replacement therapy, history of myocardial infarction or stroke, and smoking (P<0.05 for these variables) (table 1). Table 2 shows the influence of personal use of calcium supplements on the effect of calcium and vitamin D on cardiovascular end points and mortality from all causes. There were significant interactions between allocation of calcium and vitamin D and personal use of calcium supplements for clinical myocardial infarction, stroke, and the composite end point of myocardial infarction or stroke. In women not taking personal calcium supplements, the hazard ratios with calcium and vitamin D were 1.16 (P=0.04) for the composite end point of clinical myocardial infarction or coronary revascularisation, 1.16 (P=0.05) for clinical myocardial infarction or stroke, 1.22 (P=0.05) for myocardial infarction, and 1.13-1.20 for the other cardiovascular end points. By contrast, in women taking personal calcium supplements, the hazard ratios for these end points with calcium and vitamin D were 0.83-1.08. When the personal calcium supplement users were divided into three groups by daily supplement intake (1-499, 500-999, and ≥1000 mg/day), there was no evidence of a relation between the dose of personal calcium supplements and the risk of cardiovascular events with randomisation to calcium and vitamin D for these end points (fig 1) . There were no significant three-way interactions between calcium and vitamin D allocation, personal calcium supplement use, and dietary calcium intake (above or below median) for cardiovascular end points (P>0.4). We repeated these analyses in the subgroup of women not using personal calcium supplements and found no interactions between calcium and vitamin D allocation and dietary calcium intake (above or below the median) for any cardiovascular end point (P>0.5). Finally, we repeated all these analyses using dietary calcium intake grouped by tertile, and the results were similar. Together, these analyses suggest that the relation between calcium and vitamin D allocation and cardiovascular events is independent of dietary calcium intake.
RESULTS
Reanalysis of the WHI CaD Study
In a sensitivity analysis, we searched the WHI medication database to identify participants potentially taking calcium supplements not captured elsewhere, using WHI medication class codes for common calcium supplement preparations (791000, 791099, 781230, 783500, 783600, 483000, 489900, and 489910). We identified 930 participants listed as taking a calcium supplement before randomisation to calcium and vitamin D but recorded as having no supplemental intake of calcium at randomisation. When we repeated the analyses including these women classified as using personal calcium supplements, the results were similar (data not shown).
Personal vitamin D supplements were used in combination with personal calcium supplements by 44% of participants in the WHI database, and without personal calcium supplements by 3% of participants. When we repeated the analyses grouping participants by personal use of calcium and/or vitamin D supplements, the results were similar (data not shown).
Meta-analysis of calcium and vitamin D versus placebo
We analysed trials comparing co-administered calcium and vitamin D with placebo. Complete triallevel data for cardiovascular events were available for 20 090 participants from three trials-two trials with previously unpublished data gathered during preparation of our previous meta-analysis of calcium supplements, 8 9 and data from the WHI CaD Study participants who were not taking personal calcium supplements at randomisation. In total, 465 individuals had an incident myocardial infarction, 477 an incident stroke, and 911 an incident myocardial infarction or stroke during an average trial duration weighted by study size of 6.2 years. Figure 2 shows that calcium and vitamin D significantly increased the risk of myocardial infarction (relative risk 1.21, P=0.04), stroke (relative risk 1.20, P=0.05), and the composite of myocardial infarction or stroke (relative risk 1.16, P=0.02).
In a sensitivity analysis, we also included data from a study of calcium and vitamin D that only described cardiovascular event data in detail on trial withdrawals or deaths. 7 The relative risks with calcium and vitamin D were 1.22 (95% confidence interval 1.01 to 1.45, P=0.03) for myocardial infarction, 1.20 (1.00 to 1.43, P=0.05) for stroke, and 1.17 (1.03 to 1.32, P=0.02) for the composite end point. All cause mortality was available from three studies in which cardiovascular event data were available: Brazier et al, 7 Grant et al for the RECORD trial, 8 and the WHI CaD Study. In these studies, 1200 deaths occurred during follow-up, and the relative risk for death (all causes) with calcium and vitamin D was 1.01 (0.90 to 1.12, P=0.9).
Meta-analysis of calcium with or without vitamin D versus placebo As the magnitude of the risk of cardiovascular events with calcium and vitamin D was similar to that observed with calcium alone, we updated our previous meta-analysis by incorporating the results for the WHI CaD participants who were not taking personal calcium supplements at randomisation, and the data from the calcium and vitamin D arm of the Lappe study; 9 this arm was not included in our previous meta-analysis.
Patient-level data
Patient-level data were available for 24 869 people in six trials (WHI CaD and five randomised, placebo controlled trials of calcium supplements). 1 8 11-15 In total, 631 individuals had an incident myocardial infarction, 669 an incident stroke, 1248 an incident myocardial infarction or stroke, and 1765 died during a mean follow-up of 5.9 years. Figure 3 shows that calcium or calcium and vitamin D supplements increased the risk of myocardial infarction (hazard ratio 1.26, P=0.005), stroke (1.19, P=0.03), and the composite end point of myocardial infarction or stroke (1.17, P=0.005). The hazard ratio for death (all causes) was 1.04 (0.95 to 1.14, P=0.4).
The number needed to treat with calcium or calcium and vitamin D for five years to cause one incident event was 240 for myocardial infarction, 283 for stroke, and 178 for the composite end point. The corresponding number needed to treat to prevent one fracture was 302. Treating 1000 people with calcium or calcium and vitamin D for five years would cause an additional six myocardial infarctions or strokes and prevent three fractures.
Trial-level data
Complete trial-level data were available for 28 072 participants in nine trials (the WHI CaD study and eight randomised, placebo controlled trials of calcium supplements). 1 8 9 11-17 In total, 676 individuals had an incident myocardial infarction, 764 an incident stroke, 1384 an incident myocardial infarction or stroke, and 1835 died during an average trial duration weighted by study size of 5.7 years. Figure 4 shows that the results were similar to the patient-level analyses. Calcium or calcium and vitamin D supplements increased the risk of myocardial infarction (relative risk 1.24, P=0.004) and the composite of myocardial infarction/stroke (1.15, P=0.009). The relative risk of death (all causes) was 1.04 (0.95 to 1.13, P=0.5).
In a sensitivity analysis, we added all available data from three further randomised, placebo controlled trials of calcium supplements 10 18 19 and one trial of calcium and vitamin D supplements 7 (limited to data on deaths in trial or trial withdrawals) to the analysis of complete trial-level data. Data were available for 29 277 participants (WHI CaD Study, 11 trials of calcium supplements, and one trial of calcium and vitamin D): 679 individuals had an incident myocardial infarction, 768 an incident stroke, 1393 an incident myocardial infarction or stroke, and 1857 died during follow-up. With calcium or calcium and vitamin D supplements, the relative risks were 1.25 (1.08 to 1.45, P=0.003) for myocardial infarction, 1.15 (1.00 to 1.32, P=0.06) for stroke, 1.15 (1.04 to 1.27, P=0.008) for the composite of myocardial infarction or stroke, and 1.04 (0.95 to 1.13, P=0.4) for death.
DISCUSSION
In the Women's Health Initiative Calcium/Vitamin D Supplementation (WHI CaD) Study personal use of calcium supplement at randomisation significantly influenced the effect of randomisation to calcium and vitamin D on the risk of cardiovascular events. In the entire WHI cohort, there were significant interactions between calcium and vitamin D and personal calcium supplement use for myocardial infarction and for stroke. In the 46% of the WHI CaD participants who were not taking personal calcium supplements at randomisation, the hazard ratios for cardiovascular events with calcium and vitamin D ranged from 1.13 to 1.22. By contrast, in the participants taking personal calcium supplements at randomisation, allocation to calcium By itself, this analysis of the WHI CaD Study data does not provide definitive evidence of an adverse effect of calcium and vitamin D on cardiovascular events. However, when these data are pooled with previously unpublished data from two other placebo controlled trials of calcium and vitamin D, there are consistent increases in the risk of myocardial infarction and stroke that are statistically significant and are of similar size to the risks observed with calcium supplements used without vitamin D. Further, when the results for calcium and vitamin D are taken together with those from trials of calcium used as monotherapy, they provide consistent evidence from 13 randomised, placebo controlled trials involving about 29 000 participants with about 1400 incident myocardial infarctions and strokes that calcium supplements with or without vitamin D increase the risk of cardiovascular events.
The size of this increase is modest, about 25%-30% for myocardial infarction and 15%-20% for stroke, but, because of the widespread use of calcium supplements either alone or with vitamin D, even small increases in cardiovascular disease incidence may translate to a substantial population burden of disease, particularly in older age groups. Furthermore, comparisons of the benefits of calcium on fracture prevention with the risk of cardiovascular events suggest that the risk to benefit profile is unfavourable: in our analysis, treating 1000 patients with calcium or calcium and vitamin D for five years would cause an additional six myocardial infarctions or strokes (number needed to harm of 178) and prevent only three fractures (number needed to treat of 302).
Limitations of study
The current analysis has some limitations. We used the publicly accessible, limited access dataset of the WHI clinical trials for these analyses, so the analysis is limited to the information available in this dataset. Several vascular end points are potentially evaluable; we prespecified those which allowed the most accurate comparisons with previous analyses. Subgroup analysis raises several issues, including false positive results and over-interpretation of findings. 20 21 To minimise these risks, we pre-specified the variable of interest (personal calcium supplement use) for this analysis before obtaining the WHI dataset, assessed its effect using interaction tests, and followed recommended approaches for subgroup analysis and inter pretation. 21 22 The hypothesis that the use of personal calcium supplements might interact with the calcium and vitamin D treatment effect in the WHI CaD Study was based on plausibility from our finding in trials of calcium monotherapy, and deviation from normal clinical trial practice (allowing trial participants free access to the intervention being studied) is unusual and has the potential to mask both adverse and beneficial effects.
We followed the approach of the WHI authors in not adjusting P values for multiple subgroup analyses, and instead estimated the likelihood of false positive tests, 3 an approved approach for addressing multiplicity of The panels show the time to first event for 24 869 participants in five trials of calcium supplements, 1 8 11-15 and the WHI CaD Study participants not taking personal calcium supplements at baseline statistical tests. 23 Nine interaction tests were performed: if the effect of calcium and vitamin D was unrelated to personal calcium use and the end points were independent, the probability of at least one false positive interaction test is <40%. 22 Confounding is a possible explanation of our findings as subgroup analysis may interfere with the balancing effects of randomisation on potential confounders. However, within each subgroup, the baseline characteristics of the participants allocated to calcium and vitamin D seemed well matched to those allocated to placebo. In contrast, as expected, women using personal calcium differed from women not using personal calcium in a number of factors that might influence cardiovascular outcomes. However, the WHI investigators have previously reported no significant interactions with these factors, calcium and vitamin D, and risk of death from myocardial infarction or coronary heart disease-except for body mass index, with obese women having a lower risk of death from myocardial infarction or coronary heart disease with calcium and vitamin D than non-obese women. 4 Obesity does not explain our findings since it was more common in women not using personal calcium, and would have tended to obscure an interaction effect.
In the WHI CaD participants the incidence of cardiovascular events was relatively low, reflecting the comparative youth of the cohort. Thus, despite its size and long duration, the WHI CaD Study had insufficient power to detect small effect sizes, particularly when subgroups are considered. For example, in women not taking personal calcium supplements at randomisation, the study had 80% power to detect a 33% increase in clinical myocardial infarction.
The WHI CaD Study accounts for 75%-80% of the weighting in the meta-analyses of co-administered calcium and vitamin D, and 45%-55% of the weighting in the meta-analysis of calcium with or without vitamin D. However, the results for the individual studies in all the meta-analyses are quite consistent and do not suggest an undue influence of a single outlying study or WHI CaD.
Interpretation of results
For most of its participants, the WHI CaD Study assessed the impact of adding calcium and vitamin D to personal calcium supplements, effectively comparing a higher dose of calcium with a lower dose of calcium. By restricting the analyses to women not taking personal calcium supplements, we were able to estimate the effect of calcium and vitamin D on cardiovascular events, observing increased risks of these events with calcium and vitamin D. In women taking personal calcium supplements at randomisation, the addition of calcium and vitamin D did not increase cardiovascular risk, and the risk of cardiovascular events with calcium and vitamin D was also not affected by the dose of personal calcium supplements. This suggests that there may not be a dose-response relationship between calcium supplements and the risk of cardiovascular events. Thus, even doses of <500 mg/day might be associated with an increased risk of cardiovascular events similar to doses ≥1000 mg/day. This would be consistent with the notion that the abrupt change in plasma calcium concentration after supplement ingestion causes the adverse effect, rather than it being related to the total calcium load ingested. 24 25 In the entire WHI cohort there was no significant interaction between calcium and vitamin D, personal calcium supplement use, and mortality-and therefore no evidence of a difference in mortality risk with calcium and vitamin D in the subgroups defined by 25 Calcium supplements acutely increase serum calcium concentration by a modest amount, 24 an effect that is sustained during long term treatment, as evidenced by lower levels of parathyroid hormone. 15 Serum calcium concentrations are positively associated with carotid artery plaque thickness, 26 aortic calcification, 27 incidence of myocardial infarction, [28] [29] [30] and mortality. 31 These findings are consistent with observational data suggesting increased risk of cardiovascular events and death in primary hyperparathyroidism, a condition in which serum calcium concentration is elevated. 32 33 The process of vascular calcification is a complex, regulated process similar to osteogenesis. 34 It is possible that the increase in serum calcium concentrations from calcium supplements influences vascular calcification by altering regulators of calcification such as fetuin A, pyrophosphate, and bone morphogenic protein-7, or by directly binding to the calcium-sensing receptor that is expressed on vascular smooth muscle cells. 25 Exposing cultures of vascular smooth muscle cells to increased concentrations of calcium results in increased mineralisation of the cultures. 35 Supporting this hypothesis are studies of patients with renal impairment, in whom calcium supplements accelerate vascular calcification and increase mortality in both dialysis and pre-dialysis populations. [36] [37] [38] It is also possible that calcium supplements adversely affect risk of arterial thrombus formation.
Acute hypercalcaemia in rats increases blood coaguability, 39 potentially via an effect on platelets since calcium-sensing receptors are found on these cells. 40 Therefore, extracellular calcium concentrations might affect the function of several cells that are implicated in the pathogenesis of vascular events. All these possibilities require further evaluation.
Conclusions
Calcium and vitamin D supplements increased the risk of cardiovascular events in the WHI CaD participants who were not taking personal calcium supplements at the time of randomisation. When these results are taken together with the results of other clinical trials of calcium supplements, with or without vitamin D, they strongly suggest that calcium supplements modestly increase the risk of cardiovascular events, particularly myocardial infarction. These data justify a reassessment of the use of calcium supplements in older people.
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